Impact of Transcatheter Edge‐to‐Edge Repair in Patients With Cardiac Sarcoidosis: Insights From the OCEAN‐Mitral Registry

Impact of Transcatheter Edge‐to‐Edge Repair in Patients With Cardiac Sarcoidosis: Insights From the OCEAN‐Mitral Registry

Background In patients with sarcoidosis, cardiac involvement is a crucial prognostic factor leading to severe cardiovascular events. Mitral regurgitation (MR) predisposes patients to drug‐refractory heart failure; however, MR in patients with cardiac sarcoidosis (CS) has been scarcely investigated a...

Full description

Saved in:
Bibliographic Details
Main Authors: Takashi Hiruma, Mike Saji, Mamoru Nanasato, Itaru Takamisawa, Ryosuke Higuchi, Yuki Izumi, Ryo Abe, Mitsuaki Isobe, Masanori Yamamoto, Shunsuke Kubo, Masahiko Asami, Yusuke Enta, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bota, Yohei Ohno, Daisuke Hachinohe, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Toshiaki Otsuka, Kentaro Hayashida
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
cardiac sarcoidosis
MitraClip
mitral regurgitation
transcatheter edge‐to‐edge repair
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.039243
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In patients with sarcoidosis, cardiac involvement is a crucial prognostic factor leading to severe cardiovascular events. Mitral regurgitation (MR) predisposes patients to drug‐refractory heart failure; however, MR in patients with cardiac sarcoidosis (CS) has been scarcely investigated and its therapeutic approach remains unclear. This study aimed to investigate the clinical impact of transcatheter edge‐to‐edge repair in patients with CS. Methods Patients with CS‐related ventricular functional MR were compared with those with other nonischemic cardiomyopathies in the OCEAN (Optimized Catheter Valvular Intervention)‐Mitral registry in Japan. Results Among 1240 patients with nonischemic cardiomyopathy‐related ventricular functional MR, 40 (3.2%) had CS. Of these, 18 patients (45.0%) had immunosuppressive therapy. Twenty‐seven patients (67.5%) were New York Heart Association function class III/IV. Patients with CS were more likely to be younger and female, had a higher prevalence of ventricular tachyarrhythmia and cardiac resynchronization therapy, and had a larger left ventricle with more severe MR than the others. At the procedure, 38 patients (95.0%) had devices placed at the central lesion. All patients with CS were successfully treated, leading to immediate improvement of cardiac output. At 1‐year follow‐up, 89.3% had MR ≤2+ and 40.0% had New York Heart Association function class I. Despite similar outcomes between groups, greater remnant MR and fatal arrhythmic events in those with CS may be due to inadequate reverse remodeling and ongoing left ventricle damage caused by inflammation. Conclusions Transcatheter edge‐to‐edge repair is an effective heart failure treatment for patients with CS‐related MR; however, the drug‐ and cardiac device‐refractory cardiomyopathy in this population warrants careful management. Registration URL: www.umin.ac.jp/english/; Unique Identifier: UMIN000023653.
ISSN:2047-9980

Similar Items